小剂量泼尼松递增疗法对老年眼肌型重症肌无力的临床疗效观察

Abstract
Figure/Table
References (14)
Related Citation (15)

Download: PDF (0 KB) HTML (31 KB)
Export: BibTeX | EndNote (RIS)

Abstract Objective To study the clinical effect of using low doses of Prednisone with progressive therapy in the treatment of ocular myasthenia gravis in the elderly.Methods 179 elderly patients with ocular myasthenia gravis in our hospital from October 2006 to January 2015 were selected and divided into observation group(n=90)and control group(n= 89),In the observation group,the drug was administered by a low dose escalation,and in the control group was given routine oral administration.All patients were followed up for more than one year.Results Total effective rate in the observation group was 92.2%,with 77.5%in the control group,and the difference was statistically significant(P＜0.05).Recurrence rate in the observation group was 27.8%,and that of the control group was 68.5%,and the difference was statistically significant(P＜0.05).Conclusion Using low doses of incremental dosing method can improve treatment effect of elderly patients with ocular myasthenia gravis,shorten time and dose of hormone,but also can effectively reduce the incidence of adverse drug reaction.

Key words： Ocular myasthenia gravis Elderly Prednisone

	Service

	E-mail this article
	Add to my bookshelf
	Add to citation manager
	E-mail Alert
	RSS
	Articles by authors
	WANG Ai
	ZHANG Fu-qiu
	XIE Li-shi

Cite this article:

WANG Ai,ZHANG Fu-qiu,XIE Li-shi. Clinical curative effect observation of low dose Prednisone with progressive therapy on senile ocular myasthenia gravis[J]. 中国当代医药, 2017, 24(1): 43-45.

URL:

http://dangdaiyiyao.com/EN/ OR http://dangdaiyiyao.com/EN/Y2017/V24/I1/43

[1]	刘书平，李承晏，等.重症肌无力诊断和治疗最新进展[J].卒中与神经疾病，2015，22（3）：188-192.
[2]	贾建平.神经病学[M].北京：人民卫生出版社，2009：360-363.
[3]	Jakubíková M，Pitˇha J，Mareˇcková H，et al.Two-year outcome of thymectomy with or without immunosuppressive treatment in nonthymomatous myasthenia gravis and its effect on regulatory T cells[J].J Neurol Sci，2015，358（1-2）：101-106.
[4]	BedlackRS，SandersDB.Seroidtreamentprmyashenja gravis seroids have an impornnt role[J].Muscle Nerve，2002，25（1）：117-121.
[5]	中国免疫学会神经免疫学分会.重症肌无力诊断和治疗中国专家共识[J].中国神经免疫学和神经病学杂志，2012，19（6）：401-408.
[6]	杨薇，宋剑涛，高健生.益气升阳举陷法在眼科的应用[J].中国中医眼科杂志，2011，12（21）：114-115.
[7]	黄洪飞，沈陶.眼肌型重症肌无力40例辨证论治[J].中国中医眼科杂志，2010，10（3）：181-182.
[8]	刘玉祯，陈金亮，王殿华，等.重症肌无力危象96例临床分析[J].疑难病杂志，2010，9（8）：623-624.
[9]	Drachman DB，Toyka KV，Myer E.Immunoregulation with levamisole in children with frequently relapsing steroid responsive nephrotic syndrome[J].Lancet，1974，2（7894）：1409-1412.
[10]	Buttgereit F，Scheffold A.Rapid glucocorticoid effects on immune cells[J].Steroids，2002，67：529-534.
[11]	Hague DW，Humphries HD，Mitchell MA，et al.Risk factors and outcomes in cats with acquired myasthenia gravis（2001-2012）[J].J Vet Intern Med，2015，29（5）：1307-1312.
[12]	Konno S，Suzuki S，Masuda M，et al.Association between Glucocorticoid-induced osteoporosis and myasthenia gravis：a cross-sectional study[J].PLoS One，2015，10（5）：e0126579.
[13]	Utsugisawa K，Nagane Y，Suzuki S，et al.Directions for use of corticosteroids and calcineurin inhibitors against generalized myasthenia gravis：therapeutic strategies that can lead to early improvements and veer away from high-dose oral corticosteroids[J].Rinsho Shinkeigaku，2012，52（11）：1047-1050.
[14]	Zhang L，Liu J，Wang H，et al.Double filtration plasmapheresis benefits myasthenia gravis patients through an immunomodulatory action[J].J Clin Neurosci，2014，21（9）：1570-1574.